“The Future of Dermatology Therapeutics, Analysis and Market Forecasts to 2016 - Increasing Prescription Rate to Drive Revenues”. The report provides in-depth analysis of unmet needs, drivers and barriers that impact the global dermatology therapeutics market. The report analyzes the markets for dermatology therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns and sales are forecast until 2016 for the key geographies as well as select therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and also analyzes the mergers, acquisitions and licensing agreements that shape the global markets. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.
http://www.visionshopsters.com/
Scope
The scope of this report includes:
- Annualized market data for the dermatology therapeutics market from 2001 to 2009, forecast forward to 2016
- Analysis of the leading therapeutic segments. These include Acne, Psoriasis, Dermatitis, Rosacea and Skin diseases.
- Analysis of the dermatology therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain, and Japan
- Market characterization of the dermatology therapeutics market including market size, annual cost of therapy, and treatment usage patterns
- Key drivers and barriers that have a significant impact on the market
- Coverage of pipeline molecules in various phases of drug development
- Competitive benchmarking of leading companies. The key companies studied in this report are F.Hoffmann-La Roche, GlaxoSmithKline, Leo Pharma, Sanofi-Aventis, Genentech, Novartis AG, Johnson & Johnson, Galderma Pharma SA, and Merck & Co, Inc.
- Key M&A activities, licensing agreements, that have taken place between 2008 and 2009 in the global dermatology therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to
- Align product portfolio to the markets with high growth potential
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety
- Develop key strategic initiatives by understanding key focus areas of leading companies
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps
Companies Mentioned
GlaxoSmithKline plc (GSK)
Johnson & Johnson
Bayer AG
Merck & Co., Inc
Novartis AG
Sanofi-Aventis
LEO Pharma A/S
F. Hoffmann-La Roche Ltd
L’Oreal
Galderma S.A
Nestle S.A.
Table Of Contents :
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 7
1.2 List of Figures 10
2 Global Dermatology Therapeutics Market: Scope of Research 12
2.1 Introduction 12
2.2 GBI Research Report Guidance 12
3 Global Dermatology Therapeutics Market: Market Characterization 13
3.1 Market Forecasts 13
3.2 Usage Patterns 14
3.2.1 Diseased Population 14
3.2.2 Treatment Seeking Population 15
3.2.3 Diagnosis Population 16
3.2.4 Prescription Population 17
3.2.5 Therapy Usage Patterns 18
3.2.6 Geographical Distribution 19
4 Global Dermatology Therapeutics Market: US Market 20
4.1 Market Overview 20
4.2 Market Forecasts 20
4.3 Usage Patterns 21
4.3.1 Diseased Population 21
4.3.2 Treatment Seeking Population 22
4.3.3 Diagnosis Population 23
4.3.4 Prescription Population 24
4.3.5 Therapy Usage Patterns 25
5 Global Dermatology Therapeutics Market: European Market 27
5.1 Market Overview 27
5.2 Market Forecasts 27
5.3 Usage Patterns 28
5.3.1 Diseased Population 28
5.3.2 Treatment Seeking Population 29
5.3.3 Diagnosis Population 30
5.3.4 Prescription Population 31
5.3.5 Therapy Usage Patterns 32
6 Global Dermatology Therapeutics Market : Japan Market 34
6.1 Market Overview 34
6.2 Market Forecasts 34
6.3 Usage Patterns 35
6.3.1 Diseased Population 35
6.3.2 Treatment Seeking Population 36
6.3.3 Diagnosis Population 37
6.3.4 Prescription Population 38
6.3.5 Therapy Usage Patterns 39
7 Global Psoriasis Therapeutics Market 41
7.1 Market Overview 41
7.2 Market Forecasts 42
7.3 Average Cost of Therapy 43
7.4 Usage Patterns 44
7.4.1 Diseased Population 44
7.4.2 Treatment Seeking Population 45
7.4.3 Diagnosis Population 46
7.4.4 Prescription Population 47
7.4.5 Therapy Usage Patterns 48
7.5 Product Analysis 50
7.5.1 Enbrel (etanercept)
7.5.2 Humira (adalimumab)
7.5.3 Amevive (alefacept) 51
7.5.4 Remicade (infliximab)
7.5.5 Stelara (ustekinumab, CNTO1275) 51
7.5.6 Clobex (clobetasol propionate) 51
7.5.7 Tazorac (tazarotene, Avage) 51
7.5.8 Dovonex (calcipotriene)
7.5.9 Neoral (cyclosporine)
7.6 Drug Pipeline Analysis 52
7.6.1 Psoriasis Therapeutics – Phase III Clinical Pipeline 53
7.6.2 Psoriasis Therapeutics – Phase II Clinical Pipeline 54
8 Global Atopic Dermatitis Therapeutics Market 57
8.1 Market Overview 57
8.2 Market Forecasts 57
8.3 Average Cost of Therapy 59
8.4 Usage Patterns 60
8.4.1 Diseased Population 60
8.4.2 Treatment Seeking Population 61
8.4.3 Diagnosis Population 62
8.4.4 Prescription Population 63
8.4.5 Therapy Usage Patterns 64
8.5 Product Analysis 65
8.5.1 Protopic (Tacrolimus)
8.5.2 Elidel (Pimecrolimus)
8.5.3 MimyX 66
8.5.4 Atopiclair 66
8.5.5 Topical Corticosteroids 66
8.6 Drug Pipeline Analysis 66
9 Global Acne Therapeutics Market 71
9.1 Market Overview 71
9.2 Market Forecasts 71
9.3 Usage Patterns 73
9.3.1 Diseased Population 73
9.3.2 Treatment Seeking Population 74
9.3.3 Diagnosis Population 75
9.3.4 Prescription Population 76
9.3.5 Therapy Usage Patterns 77
9.4 Product Analysis 78
9.5 Drug Pipeline Analysis 78
10 Global Rosacea Disease Therapeutics Market 84
10.1 Market Overview 84
10.2 Market Forecasts 84
10.3 Average Cost of Therapy 85
10.4 Usage Patterns 86
10.4.1 Diseased Population 86
10.4.2 Treatment Seeking Population 87
10.4.3 Diagnosis Population 88
10.4.4 Prescription Population 89
10.4.5 Therapy Usage Patterns 90
10.5 Product Analysis 91
10.6 Drug Pipeline Analysis 92
11 Global Dermatology Therapeutics Market: Market Drivers and Restraints 95
11.1 Market Drivers 95
11.1.1 Steady Increase in the Elderly Population 95
11.1.2 Stable Increase in Incidence Rates for Dermatology Diseases 96
11.1.3 Increase in Awareness Levels of Disease Progression and Etiology 96
11.2 Market Restraints 96
11.2.1 Entry of Generics Pose a Serious Problem for Primary Manufacturers 96
11.2.2 Presence of Serious Side Effects for Certain Classes of Therapeutic drugs 96
12 Global Dermatology Therapeutics Market : Key Market Trends 97
13 Global Dermatology Therapeutics Market: Competitive Landscape 98
13.1 Overview 98
13.2 Market Share Analysis 98
13.3 Competitive Profiling 98
13.3.1 GlaxoSmithKline plc (GSK) 98
13.3.2 Johnson & Johnson 100
13.3.3 Bayer AG 102
13.3.4 Merck & Co., Inc 103
13.3.5 Novartis AG 105
13.3.6 Sanofi-Aventis 106
13.3.7 LEO Pharma A/S 107
13.3.8 F. Hoffmann-La Roche Ltd 108
13.3.9 L’Oreal 109
13.3.10 Galderma S.A. 109
13.3.11 Nestle S.A. 110
To know more about this report & to buy a copy please visit:
http://www.visionshopsters.com/
